GI Innovation Inc
358570
Company Profile
Business description
GI Innovation Inc is a bio-venture company that researches and develops protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART platform.
Contact
Songpa-daero 167
Room 1116 of A-dong
Songpa-gu
Seoul05855
KORT: +82 24042003
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
80
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,194.90 | 12.40 | -0.13% |
| CAC 40 | 8,146.75 | 112.19 | -1.36% |
| DAX 40 | 25,038.25 | 258.88 | -1.02% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,199.24 | 36.05 | -0.35% |
| HKSE | 26,563.90 | 281.06 | -1.05% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,583.57 | 352.60 | -0.65% |
| NZX 50 Index | 13,580.29 | 137.81 | -1.00% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,874.50 | 9.20 | -0.10% |
| SSE Composite Index | 4,114.00 | 12.09 | 0.29% |